| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:30 - 08:40 | Opening Remarks |
Chung-Liang Shih
Yen-Shen Lu
Fang-Ming Chen
|
Chung-Liang Shih
Yen-Shen Lu
Fang-Ming Chen
|
Video | |||
| 08:40 - 09:00 | [Keynote Speech] Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform |
Chung-Liang Shih
|
Ming-Feng Hou
|
Video | |||
| 09:00 - 09:30 | Session(1) Early Onset Breast Cancer: Current Knowledge and Gaps |
Kyong Hwa Park
|
King-Jen Chang
|
Video | |||
| 09:30 - 10:00 | Session (1) Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC |
Joohyuk Sohn
|
Shyr-Ming Sheen-Chen
|
||||
| 10:00 - 10:40 | Session (1) Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration |
Nancy Lin
|
Tsu-Yi Chao
|
||||
| 10:40 - 11:00 | Coffee Break | ||||||
| 11:00 - 11:40 | Session (2) Navigating the Complexities of Treatment in HR+ HER2- Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs |
Hope S. Rugo
|
Hsien-Tang Yeh
|
||||
| 11:40 - 12:20 | Session (2) The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Broadening the Impact of CDK4/6 Inhibitors |
Peter Fasching
|
Fang-Ming Chen
|
Video | |||
| 12:20 - 13:05 | Luncheon Symposium (1) Maximizing Treatment Benefit and Overall Survival in HER2- Negative MBC |
Hsu-Huan Chou
|
Dar-Ren Chen
|
||||
| 13:05 - 13:20 | Coffee Break | ||||||
| 13:20 - 14:00 | Session (2) The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2- Node+ High Risk Early Breast Cancer |
Michael Gnant
|
Shin-Cheh Chen
|
Video | |||
| 14:00 - 14:30 | Session (2) Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer |
Marc Thill
|
Shigehira Saji
|
Video | |||
| 14:30 - 15:10 | Session (2) Choosing Wisely:TS-1 for HR+ EBC |
Kun-Ming Rau
|
Hsien-Kun Chang
|
||||
| 15:10 - 15:30 | Coffee Break | ||||||
| 15:30 - 16:10 | Session (2) Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine |
Naoto T. Ueno
|
Chiun-Sheng Huang
|
Video | |||
| 16:10 - 16:50 | Session (2) The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer |
Peter Schmid
|
Ling-Ming Tseng
|
||||
| 16:50 - 17:30 | Session (3) Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC) |
Naoto T. Ueno
|
Yen-Shen Lu
|
Video | |||
| 17:30 - 18:00 | Session (3) Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer |
Giampaolo Bianchini
|
Ta-Chung Chao
|
Video |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 10:30 - 10:40 | Epigenetic inhibition of PLK1 by Luteolin-7-glucoside suppresses Estrogen receptor-positive breast cancer progression and proliferation. |
Joseph Lin
|
|||||
| 10:40 - 10:50 | Preliminary spatial transcriptomic analysis for invasive lobular carcinoma |
Chi-Cheng Huang
|
|||||
| 10:50 - 11:00 | The Role of miRNAs in breast cancer across distinct subtypes via microarray analysis |
Chi-Cheng Huang
|
|||||
| 11:00 - 11:10 | Discovery of BRCA Founder Variants in Taiwanese Cancer Patients: Clinical Actionability and Population Screening Implications from 84-Gene Panel Analysis |
Peng-Yu Chen
|
|||||
| 11:10 - 11:20 | Clinical Relevance of PIK3CA Mutations in Modulating CDK4/6 Inhibitor Efficacy in HR+/HER2− Advanced Breast Cancer |
Sheng-Fan Wang
|
|||||
| 11:20 - 11:30 | Toosendanin inhibits the metastatic progression of triple-negative breast cancer by abrogating ADORA2A-driven neurogenesis |
Juan Zhang
|
|||||
| 11:30 - 11:40 | The adoption rate and management of treatment-emergent adverse event during adjuvant abemaciclib treatment in Japanese women with high-risk HR+HER2- early breast cancer |
Kaori Tane
|
|||||
| 11:40 - 11:50 | Features of Breast Cancer Across Age Groups in a Japanese Hospital: Comparison with Global Trends |
Hitomi Mori
|
|||||
| 11:50 - 12:00 | Evaluation of a Novel Diagnostic Kit Using the Semi-Dry Dot-Blot Method with an Automated Reader for Detecting Breast Cancer Metastases in Sentinel Lymph Nodes: A Combined Analysis of Two Multicenter Prospective Studies in Japan |
Ryota Otsubo
|
|||||
| 12:00 - 12:10 | Real-World Effectiveness and Safety of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: Updated Data from a Single-Center Taiwanese Cohort |
Han-Fang Cheng
|
|||||
| 12:10 - 12:20 | From AI to Single-Cell and Multi-Omics: RAC1 as a Prognostic and Therapeutic Target in Breast Cancer Oncometabolism and Immunomodulation |
Hung-Yu Lin
|
|||||
| 12:20 - 12:30 | Impact of psychiatric disorders on metastatic breast cancer survival: the critical role of supportive psychiatric management |
Cho-Hao Lee
|
|||||
| 12:30 - 13:30 | Lunch & Coffee Break | ||||||
| 13:10 - 13:20 | Adipocyte-Derived SERPINE1 Drives Obesity-Associated Breast Cancer Progression: Integrative Transcriptomic and Functional Analyses |
Kian Hwee Chong
|
|||||
| 13:20 - 13:30 | Immunogenic Effect of PIK3CA Mutations in Breast Cancer: Implications for Neoantigens, HLA Types, and Immune Microenvironment |
Hsing-Wu Chen
|
|||||
| 13:30 - 13:40 | Use of pre-treatment MRI-derived radiomics to predict the final treatment response to neoadjuvant chemotherapy in breast cancer patients: a preliminary study |
Jane Wang
|
|||||
| 13:40 - 13:50 | SHMT2 Promotes Breast Cancer Metastasis through Metabolic Reprogramming and EMT Activation |
Yen-Dun Tzeng
|
|||||
| 13:50 - 14:00 | Mature B cell with the antigen presenting signature predicts pathologic complete response and survival in early Her2-positive breast cancer treated with neoadjuvant therapy |
Po-Han Lin
|
|||||
| 14:00 - 14:10 | Novel HER2 activity linked to therapy resistance and brain metastasis |
Huynh Kieu Thanh
|
|||||
| 14:10 - 14:20 | Disrupting DDB2–DNA Interaction by Lapatinib Enhances Chemotherapy Sensitivity |
Yu-Hao He
|
|||||
| 14:20 - 14:30 | Age-informed real-world evidence reveals TP53 mutation confers resistance to CDK4/6 but not immune checkpoint inhibitors in ER-positive/HER2-negative breast cancer |
Masanori Oshi
|
|||||
| 14:30 - 14:40 | Dual Metabolic Reprogramming in Metastatic Breast Cancer: The Critical Role of ANT2 in Supporting Energy Homeostasis and Progression |
Chia-Jung Li
|
|||||
| 14:40 - 15:00 | Coffee Break | ||||||
| 15:00 - 15:10 | Spatial transcriptomics reveals clone-specific features of primary and metastatic tumors in triple-negative breast cancer |
Yu-Wen Weng
|
|||||
| 15:10 - 15:20 | SCD1-driven lipid metabolic reprogramming confers resistance to HER2-targeted therapies in breast cancer |
Meng-Xia Su
|
|||||
| 15:20 - 15:30 | Sacituzumab govitecan in HR-positive/HER2-negative breast cancer cells with resistance to PI3K or AKT inhibitors |
Wei-Pang Chung
|
|||||
| 15:30 - 15:40 | Tartrate-resistant acid phosphatase 5 regulates the metabolic flexibility of macrophages in the tumor microenvironment, thereby influencing their functional fate and modulating tumor growth. |
Ming-Shen Dai
|
|||||
| 15:40 - 15:50 | What We Learned from AJCC 8th Edition Cancer Staging System for Our Breast Cancer Patients (2005-2021) |
Ben-Long Yu
|
|||||
| 15:50 - 16:00 | Cohort Study on Adjuvant Treatment for Premenopausal HR positive/HER2 negative Breast Cancer Patients with 1-3 Positive Nodes |
Ping-Fu Yang
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 11:10 - 11:50 | Let’s Meet the Master (1) Marc Thill | ||||||
| 13:30 - 14:10 | Let’s Meet the Master (2) Judy C. Boughey |
Wen-Ling Kuo
|
|||||
| 14:40 - 15:20 | Let’s Meet the Master (3) Giampaolo Bianchini |
Jiun-I Lai
|
|||||
| 16:10 - 16:50 | Let’s Meet the Master (4) Peter Fasching |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:10 - 08:50 | Breakfast Symposium: Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care |
Ming-Shen Dai
|
Kun-Ming Rau
|
Video | |||
| 08:50 - 09:20 | Session (4) The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer |
Mehra Golshan
|
Takashi Ishikawa
|
||||
| 09:20 - 09:50 | Session (4) Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy |
Judy C. Boughey
|
Jyh-Cherng Yu
|
Video | |||
| 09:50 - 10:05 | Coffee Break | ||||||
| 10:05 - 10:35 | Session (4) Omission of Radiation Therapy Post Breast Conserving Surgery |
Boon Chua
|
Shou-Tung Chen
|
Video | |||
| 10:35 - 11:05 | Session (4) Setting the Standard for the Future of Cancer Surgery |
Kelly Hunt
|
Fiona Tsui-Fen Cheng
|
||||
| 11:05 - 11:45 | Session (5) Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline |
Sherene Loi
|
Chin-Yao Lin
|
||||
| 11:45 - 12:25 | Session (5) A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates |
Sung Bae Kim
|
Chun-Yu Liu
|
Video | |||
| 12:25 - 13:10 | Luncheon Symposium (2) Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care |
Chih-Chiang Hung
|
Ming-Yang Wang
|
||||
| 13:10 - 13:30 | Coffee Break | ||||||
| 13:30 - 14:10 | Session (6) Breaking the Ceiling: Strategies to Reduce Recurrence in HER2+ Early Breast Cancer |
Chi-Cheng Huang
|
Yuan-Ching Chang
|
||||
| 14:10 - 14:50 | Session (6) HER2+ Breast Cancer in the Era of Biosimilars: Optimizing Access with Herzuma |
Ching-Ting Wei
|
Chao-Ming Hung
|
Video | |||
| 14:50 - 15:05 | Coffee Break | ||||||
| 15:05 - 15:45 | Session (6) Optimizing HER2 Management Among Breast Cancer Patients: Role of Trastuzumab in Evolving Therapeutic Paradigms |
Paul Cornes
|
Wen-Hung Kuo
|
Video | |||
| 15:45 - 16:25 | Session (6) From Evidence to Action: Impact of Xgeva in Breast Cancer Bone Metastasis |
I-Chen Tsai
|
Kuo-Ting Lee
|
Video | |||
| 16:25 - 16:45 | Award Ceremony | ||||||
| 16:45 - 17:00 | Closing | Video |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 09:35 - 10:15 | Reimbursement Expansion of Pegfilgrastim for FN Prevention in Non–Myeloid Malignancies: Broader Access, Better Outcomes |
Chih-Hao Huang
|
Chih-Chiang Hung
|
||||
| 10:15 - 10:55 | New Horizons in First-Line Management of HR+ mBC with PIK3CA Mutation |
Shih-Che Shen
|
Yen-Yang Chen
|
Video | |||
| 10:55 - 11:35 | Immunotherapy in Early TNBC: Evolving Evidence, Maximizing Benefit Through Thoughtful Patient Selection |
Han-Fang Cheng
|
Ling-Ming Tseng
|
Video | |||
| 11:35 - 12:15 | Suture Scaffold Technique in Breast-Conserving Surgery: Safety, Cosmetic Outcomes, and Lessons from Over 2,000 Cases |
Reiko Mitsueda
|
Chen-Hsiang Chang
|
Video | |||
| 12:15 - 13:10 | Emerging Approaches in ER+/HER2- Metastatic Breast Cancer Management |
Soo Chin Lee
|
Wei-Pang Chung
|
Video | |||
| 13:10 - 13:50 | Not all CDK4/6i are created equal: Optimizing HR+ HER2- Metastatic Breast Cancer Treatment Outcomes |
Michael Gnant
|
Ching-Hung Lin
|
Video | |||
| 13:50 - 14:30 | Oncofertility Needs and Supportive Care for Breast Cancer Women in Reproductive Age: The Experience from Hope Foundation for Cancer Care in Taiwan |
Shiuyu C. Katie Lee
|
Yao-Jen Chang
|
||||
| 14:30 - 15:10 | Survivorship in Breast Cancer: Physical Activity and Alcohol Consumption and Breast Cancer |
Tristen Park
|
Liang-Chih Liu
|
||||
| 15:10 - 15:50 | Cardio-Oncology at NCKUH: Breast Cancer and Cardiotoxicity - Progress and Future Directions |
Yu-Ling Hsu
|
Chin-Sheng Hung
|
Video |
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 11:30 - 12:30 | Let’s Meet the Master (5) Boon Chua |
Boon Chua
|